Routine statins use is associated with less adverse outcome in patients above 70 years of age admitted to hospital with COVID-19.
Adverse outcome
COVID-19
Older adults
SARS-CoV-2
Statins
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
07 08 2023
07 08 2023
Historique:
received:
22
08
2022
accepted:
19
07
2023
medline:
9
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to multiorgan insufficiency and death, particularly among the older adults. Statins have been suggested as potentially protective drugs due to their pleotropic effects, but the actual benefit of statin use among the older population in this setting is not clear. This study aimed to evaluate the association between preadmission statin use and the presentation and clinical outcomes of hospitalized COVID-19 patients older than 70 years of age. A historical cohort study of all patients above 70 years of age who were hospitalized with COVID-19 infection in a large academic hospital between March and August 2020 was performed. The association between preadmission statin use and patients' presentation and adverse outcome was studied. Adverse outcome was defined as any of the following: shock, invasive or non-invasive ventilation, organ insufficiency, myocardial infarction, cerebrovascular accident, in-hospital or 30-day post-admission mortality, hospital stay longer than the median length of stay of all COVID-19 patients, referral to nursing home or rehabilitation center. Seventy-two (44%) of the 163 studied patients (median age 82 years, 45% males) had been preadmission treated with statins. The statin-treated patients (STP) had a higher prevalence of diabetes (40% vs 24%, p = 0.028) and cardiovascular disease (58% vs. 34%, p = 0.002). Seventy two percent of the STP had adverse outcome, compared to 86% of the non-STP (p = 0.033). After adjustment for potential confounders, prior statin use was associated with decreased risk for an adverse outcome (odds ratio = 0.4, 95% confidence interval 0.18-0.92, p = 0.03). The preadmission use of statins was associated with a lower risk of adverse outcome in older adults hospitalized with COVID-19. Continuation of statin treatment might be implemented for risk reduction of adverse outcomes in the older population in the era of new SARS-CoV-2 variants and less effective vaccines.
Sections du résumé
BACKGROUND
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to multiorgan insufficiency and death, particularly among the older adults. Statins have been suggested as potentially protective drugs due to their pleotropic effects, but the actual benefit of statin use among the older population in this setting is not clear. This study aimed to evaluate the association between preadmission statin use and the presentation and clinical outcomes of hospitalized COVID-19 patients older than 70 years of age.
METHODS
A historical cohort study of all patients above 70 years of age who were hospitalized with COVID-19 infection in a large academic hospital between March and August 2020 was performed. The association between preadmission statin use and patients' presentation and adverse outcome was studied. Adverse outcome was defined as any of the following: shock, invasive or non-invasive ventilation, organ insufficiency, myocardial infarction, cerebrovascular accident, in-hospital or 30-day post-admission mortality, hospital stay longer than the median length of stay of all COVID-19 patients, referral to nursing home or rehabilitation center.
RESULTS
Seventy-two (44%) of the 163 studied patients (median age 82 years, 45% males) had been preadmission treated with statins. The statin-treated patients (STP) had a higher prevalence of diabetes (40% vs 24%, p = 0.028) and cardiovascular disease (58% vs. 34%, p = 0.002). Seventy two percent of the STP had adverse outcome, compared to 86% of the non-STP (p = 0.033). After adjustment for potential confounders, prior statin use was associated with decreased risk for an adverse outcome (odds ratio = 0.4, 95% confidence interval 0.18-0.92, p = 0.03).
CONCLUSIONS
The preadmission use of statins was associated with a lower risk of adverse outcome in older adults hospitalized with COVID-19. Continuation of statin treatment might be implemented for risk reduction of adverse outcomes in the older population in the era of new SARS-CoV-2 variants and less effective vaccines.
Identifiants
pubmed: 37550638
doi: 10.1186/s12877-023-04183-8
pii: 10.1186/s12877-023-04183-8
pmc: PMC10405432
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
473Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Crit Care Med. 2011 Nov;39(11):2440-6
pubmed: 21725239
J Clin Lipidol. 2021 Jan-Feb;15(1):68-78
pubmed: 33390341
J Infect Dis. 2022 Jan 5;225(1):19-29
pubmed: 34665852
Lancet. 2019 Feb 2;393(10170):407-415
pubmed: 30712900
Clin Chim Acta. 2020 Feb;501:33-41
pubmed: 31816288
Biomed Res Int. 2021 Sep 23;2021:1901772
pubmed: 34568488
Circ Res. 2017 Jan 6;120(1):229-243
pubmed: 28057795
Cardiovasc Drugs Ther. 2022 Dec;36(6):1165-1173
pubmed: 34524566
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Rheumatol Ther. 2017 Jun;4(1):133-149
pubmed: 27900570
Int J Infect Dis. 2021 Sep;110:374-381
pubmed: 34375760
J Am Heart Assoc. 2021 Nov 2;10(21):e022330
pubmed: 34689613
N Engl J Med. 2007 Apr 26;356(17):1723-35
pubmed: 17460226
PLoS Med. 2021 Oct 14;18(10):e1003820
pubmed: 34648516
Crit Care Med. 2019 Aug;47(8):1089-1096
pubmed: 31206358
J Am Med Dir Assoc. 2020 Jul;21(7):909-914.e2
pubmed: 32674818
J Pers Med. 2021 Feb 10;11(2):
pubmed: 33578937
J Clin Lipidol. 2021 May-Jun;15(3):451-459
pubmed: 33726984
PLoS One. 2013;8(1):e52929
pubmed: 23349694
Medicina (Kaunas). 2019 Oct 30;55(11):
pubmed: 31671689
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Antimicrob Chemother. 2008 Apr;61(4):774-85
pubmed: 18263570
N Engl J Med. 2021 Nov 4;385(19):1737-1749
pubmed: 34554658
Trends Mol Med. 2008 Jan;14(1):37-44
pubmed: 18068482
J Cardiovasc Pharmacol. 2020 May;75(5):359-367
pubmed: 32282502
Clin Microbiol Infect. 2019 Mar;25(3):280-289
pubmed: 30472427
BMJ Open. 2020 Dec 4;10(12):e044421
pubmed: 33277291
J Clin Med. 2021 Apr 01;10(7):
pubmed: 33916281
Pathogens. 2020 Sep 17;9(9):
pubmed: 32957539
Intern Emerg Med. 2022 Apr;17(3):685-694
pubmed: 34637080
Arterioscler Thromb Vasc Biol. 2021 Mar;41(3):e175-e182
pubmed: 33535790
BMJ. 2022 Jan 7;376:e068407
pubmed: 34996756